Keros Therapeutics (KROS) News Today

Renaissance Technologies LLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 14,300 shares of the company's stock, valued at approximately

Marshall Wace LLP trimmed its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 91.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,377 shares of the company's stock after sellin

Squarepoint Ops LLC acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,832 shares of the company'

Nantahala Capital Management LLC raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 28.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 378,807 shares of the company's

Point72 Asset Management L.P. reduced its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 61.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 370,350 shares of the c

Blue Owl Capital Holdings LP trimmed its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 8.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,633 shares of the company's stock after selling

Fred Alger Management LLC lessened its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 25.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,993 shares of the company's

Darwin Global Management Ltd. boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 6.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,525,902 shares of the company's s

Integral Health Asset Management LLC lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 112.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,000 shares of the compa

Guggenheim began coverage on Keros Therapeutics in a report on Monday. They set a "buy" rating and a $96.00 price target on the stock.

American Century Companies Inc. raised its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 24.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,170

Bank of New York Mellon Corp boosted its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 18.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 118,388 shares of the company's stock after buying a

Bank of America decreased their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating on the stock in a research note on Thursday.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have been assigned an average recommendation of "Buy" from the seven brokerages that are covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1 year

Candriam S.C.A. cut its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 32.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 441,855 shares of the company's stock after selling 210,144

Keros Therapeutics (NASDAQ:KROS) Shares Up 7.6%

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 3,490,000 shares, a growth of 10.1% from the July 31st total of 3,170,000 shares. Based on an average daily trading volume, of 360,100 shares, the short-interest ratio is presently 9.7 days.

Assenagon Asset Management S.A. acquired a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 24,459 shares of the company's stock, valued at appr

SG Americas Securities LLC purchased a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,633 shares of the company's stock, valued at

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 3,170,000 shares, an increase of 10.5% from the July 15th total of 2,870,000 shares. Based on an average trading volume of 343,600 shares, the days-to-cover ratio is presently 9.2 days.

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for shares of Keros Therapeutics in a report released on Thursday, August 8th. HC Wainwright analyst A. Fein now forecasts that the company will post

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Analysts at Leerink Partnrs dropped their FY2028 EPS estimates for shares of Keros Therapeutics in a report released on Wednesday, August 7th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of $1.83 per share

Keros Therapeutics (NASDAQ:KROS - Get Free Report) announced its earnings results on Wednesday. The company reported ($1.25) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.25). The business had revenue of $0.04 million during the quarter. During the same quarter in the prior year, the company earned ($1.27) EPS.

Vanguard Group Inc. boosted its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 7.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,545,758 shares of the company's stock after purchasing an a

Price T Rowe Associates Inc. MD raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 17.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,218,504 shares of the company's stock after purchasing an addit

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 2,870,000 shares, a growth of 12.5% from the June 30th total of 2,550,000 shares. Based on an average daily trading volume, of 343,400 shares, the short-interest ratio is presently 8.4 days.

Keros Therapeutics (NASDAQ:KROS) Sees Large Volume Increase

Russell Investments Group Ltd. reduced its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 12.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 82,352 shares of the company's stock afte

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has received an average rating of "Buy" from the eight research firms that are covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have iss

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have received an average rating of "Buy" from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year pr

Oppenheimer started coverage on Keros Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $102.00 price objective on the stock.

Keros Therapeutics (NASDAQ:KROS) Stock Price Down 8.8%

Parkman Healthcare Partners LLC grew its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 20.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 360,467 shares of the